Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Rhythm Pharmaceuticals, Inc. (RYTM)

23.72   0.93 (4.08%) 09-26 15:46
Open: 22.86 Pre. Close: 22.79
High: 24.91 Low: 22.76
Volume: 706,351 Market Cap: 1,398(M)

Technical analysis

as of: 2023-09-26 3:22:11 PM
Short-term rate:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Mid-term rate:       
Target: Six months: 30.42     One year: 32.99
Support: Support1: 22.47    Support2: 18.7
Resistance: Resistance1: 26.04    Resistance2: 28.25
Pivot: 24.49
Moving Average: MA(5): 23.48     MA(20): 24.94
MA(100): 20.3     MA(250): 22.83
MACD: MACD(12,26): -0.2     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 18.4     %D(3): 11
RSI: RSI(14): 48.2
52-week: High: 34.99  Low: 15.5
Average Vol(K): 3-Month: 710 (K)  10-Days: 657 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ RYTM ] has closed above bottom band by 37.7%. Bollinger Bands are 17.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 23.47 - 23.59 23.59 - 23.68
Low: 22.17 - 22.32 22.32 - 22.45
Close: 22.57 - 22.81 22.81 - 23

Company Description

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Headline News

Tue, 26 Sep 2023
Is Rhythm Pharmaceuticals Inc (RYTM) a Winner in the Biotechnology Industry? - InvestorsObserver

Mon, 25 Sep 2023
RBC Capital Analyst Reaffirms Confidence in BioCryst Pharma with ... - Best Stocks

Fri, 22 Sep 2023
Rhythm Pharmaceuticals Presents New Data at ESPE 2023 - BioSpace

Tue, 12 Sep 2023
Great Point Partners LLC Takes Position in Rhythm Pharmaceuticals ... - MarketBeat

Wed, 06 Sep 2023
ExodusPoint Capital Management LP Acquires Stake in Rhythm ... - Best Stocks

Wed, 06 Sep 2023
Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code ... - BioSpace

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 59 (M)
Shares Float 45 (M)
% Held by Insiders 0.4 (%)
% Held by Institutions 108.1 (%)
Shares Short 10,650 (K)
Shares Short P.Month 12,410 (K)

Stock Financials

EPS -3.17
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.2
Profit Margin (%) 0
Operating Margin (%) -412.5
Return on Assets (ttm) -38.5
Return on Equity (ttm) -96.5
Qtrly Rev. Growth 112
Gross Profit (p.s.) 0.36
Sales Per Share 0.74
EBITDA (p.s.) -3.04
Qtrly Earnings Growth 0
Operating Cash Flow -159 (M)
Levered Free Cash Flow -102 (M)

Stock Valuations

PE Ratio -7.61
PEG Ratio 0.8
Price to Book value 7.51
Price to Sales 32.36
Price to Cash Flow -8.94

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.